Fast Track designation supported by positive results from the KT-621 BroADen Phase 1b atopic dermatitis (AD) patient trial KT-621 BROADEN2 Phase 2b AD trial ongoing, with data expected to be reported ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback